INS and Other metabolic disease: Additionally, PPARγ reportedly plays an important role in improving insulin sensitivity [69], with clinical studies showing improvements in metabolic disorders and reduced inflammatory responses in type 2 diabetes patients treated with the PPARγ agonist RG within 6 months after receiving coronary artery intervention [70].